Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

YR 201

Next Previous
X
Search
Drug Profile

YR 201

Alternative Names: YR-201

Latest Information Update: 14 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator YIRUI Pharmaceutical Technology
  • Class Anti-infectives; Anti-inflammatories; Eye disorder therapies; Small molecules
  • Mechanism of Action G protein-coupled receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Chronic obstructive pulmonary disease; Ocular inflammation; Pneumonia; Retinal disorders

Most Recent Events

  • 21 Oct 2024 YIRUI Pharmaceutical Technology expects NDA for chronic obstructive pulmonary disease and pneumonia in 2028 or 2029 (Inhalation) (YIRUI Pharmaceutical Technology pipeline, October 2024)
  • 21 Oct 2024 YIRUI Pharmaceutical Technology expects NDA for retinal disorders and ocular inflammation in 2028 (Ophthalmic) (YIRUI Pharmaceutical Technology pipeline, October 2024)
  • 21 Oct 2024 YIRUI Pharmaceutical Technology plans to initiate clinical trials for Chronic obstructive pulmonary disease and Pneumonia in second half of 2024 (Inhalation) (YIRUI Pharmaceutical Technology pipeline, October 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top